799PDPhase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). (23rd October 2018) - Tagawa, S T; Vallabhajosula, S; Jhanwar, Y; Hackett, A; Oromendia, C; Naiz, M J; Goldsmith, S J; Nanus, D M; Beltran, H; Molina, A M; Faltas, B; Sreekumar, J; et al.